What are the recommended HPV vaccination guidelines, including age range, dosing schedule, preferred vaccine, and contraindications?

HPV Vaccination Recommendations

Routine HPV vaccination should begin at age 11–12 years using a 2-dose schedule for all children, with catch-up vaccination through age 26 years using a 3-dose schedule if initiated at age 15 or older. 1

Age-Based Vaccination Schedule

Routine Vaccination (Ages 9–14)

• Start vaccination at age 11–12 years, though initiation as early as age 9 is permitted and may improve series completion rates 2, 1
• 2-dose schedule: Administer doses at month 0 and month 6–12 (minimum 5-month interval between doses) for individuals who receive the first dose before their 15th birthday 1
• This simplified schedule applies to immunocompetent children only 1

Catch-Up Vaccination (Ages 15–26)

• 3-dose schedule required: Month 0, month 1–2, and month 6 1
• Minimum intervals: ≥4 weeks between doses 1 and 2, ≥12 weeks between doses 2 and 3, ≥24 weeks between doses 1 and 3 1
• All persons through age 26 should receive catch-up vaccination if not adequately vaccinated, regardless of prior sexual activity 2, 1
• Prior HPV exposure is not a contraindication—most individuals remain unexposed to at least some vaccine-covered types even after sexual debut 1

Shared Clinical Decision-Making (Ages 27–45)

• Universal catch-up vaccination is NOT recommended for adults over age 26 2, 1
• For ages 27–45, engage in shared decision-making focused on individuals at higher risk for new HPV exposure (new sexual partners, non-monogamous relationships) 1
• Vaccine effectiveness is substantially lower in this age group due to prior HPV exposure 1
• HPV vaccines are not licensed for use beyond age 45 2, 1

Special Populations Requiring Modified Schedules

Immunocompromised Individuals

• Always use a 3-dose series (0,1–2,6 months) regardless of age at initiation for: 1, 3
  • HIV infection
  • Sickle cell disease
  • Solid organ transplant recipients
  • Hematopoietic stem cell transplant recipients
  • End-stage renal disease
  • Systemic lupus erythematosus
  • Other causes of immunosuppression 4
• Do not restart the series if interrupted—simply give the next dose as soon as possible 3

Pregnancy and Breastfeeding

• Defer HPV vaccination until after pregnancy 2, 1
• Routine pregnancy testing before vaccination is not required 2, 1
• Vaccination is safe during breastfeeding and may be administered without concern 2, 1

Vaccine Formulation and Administration

Current Vaccine

• 9-valent HPV vaccine (9vHPV, Gardasil-9) is the only formulation distributed in the United States since 2016 2, 1
• Protects against HPV types 6,11,16,18,31,33,45,52, and 58 1

Administration Details

• Dose: 0.5 mL intramuscularly into the deltoid muscle 1
• Shake vial well before administration 3
• May be co-administered with other age-appropriate vaccines (Tdap, meningococcal conjugate) using separate syringes at different anatomic sites 1
• Have patients remain seated or supine for 15 minutes post-injection to reduce syncope risk in adolescents 1, 3

Contraindications and Precautions

Absolute Contraindication

• Severe allergic reaction (anaphylaxis) to yeast or any vaccine component 1, 3

Precautions (Defer Vaccination)

• Moderate or severe acute illness until recovery 1, 3
• Pregnancy (defer until after delivery) 2, 1

NOT Contraindications

• Breastfeeding 2, 1
• Prior sexual activity 1
• Abnormal or equivocal Pap test results 3
• Immunosuppression (this is an indication for modified 3-dose schedule) 1, 3
• No prevaccination HPV or Pap testing is recommended 2

Critical Clinical Pitfalls

Common Errors to Avoid

• Do not use 2-dose schedule for immunocompromised patients—they require 3 doses even if starting before age 15 1, 3
• Do not withhold vaccination from sexually active individuals—they likely remain unexposed to multiple vaccine types 1
• Do not skip catch-up vaccination for ages 13–26—this remains a routine recommendation, not discretionary 2, 1
• Do not routinely vaccinate adults over age 26—this requires individualized risk assessment and shared decision-making 2, 1

Screening Relationship

• HPV vaccination does NOT replace cervical cancer screening—vaccinated individuals must continue following current screening guidelines 2, 1
• Screening recommendations remain unchanged regardless of vaccination status 2

Efficacy and Safety Profile

• HPV vaccines demonstrate >99% efficacy against vaccine-type HPV infection when administered before exposure 5
• Vaccines are highly immunogenic and safe, with local injection site reactions being the most common adverse effect 6, 5
• Real-world effectiveness studies show notable decreases in HPV 6/11/16/18 prevalence among vaccinated populations 6
• The 9-valent vaccine provides additional protection against HPV 31/33/45/52/58 compared to earlier formulations 6